Eli Lilly (NYSE:LLY) Full Year 2023 Results

Key Financial Results

• Revenue: US$34.1b (up 20% from FY 2022).
• Net income: US$5.24b (down 16% from FY 2022).
• Profit margin: 15% (down from 22% in FY 2022).
• EPS: US$5.82 (down from US$6.93 in FY 2022).

LLY Products In Clinical Trials

• Phase II: 23.
• Phase III: 13.

LLY Post-Clinical Trial Products

• Pre-registration: 3.
• Approved (during full year): 3.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Eli Lilly Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates by 3.9%.

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are up 1.6% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Eli Lilly has 2 warning signs we think you should be aware of.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.